Important information about the discontinuation of Daklinza

Bristol Myers Squibb has or is discontinuing Daklinza (daclatasvir) in countries where the product is no longer routinely prescribed or there are other therapeutic options available. Daklinza played a significant role in providing a new era of treatment, offering patients across the globe the potential for cure from chronic HCV infection.  New Hepatitis C treatments have built on the safety and efficacy profile of Daklinza to offer shorter treatment durations and a reduced pill burden, and thus providing patients more options for a potential cure.  

Following the lapse / withdrawal of the marketing authorization in each country, the patents in that country will also be allowed to lapse. In the interim period between the lapse / withdrawal of a marketing authorization and patent expiry, Bristol Myers Squibb will not enforce its Daklinza patents in that country. This policy is specific for Daklinza moving forward.